BACKGROUND: To evaluate the effect of radiotherapy (RT) in association with complete second look operation, histologically confirmed, on outcome of patients with IRS Gr.III non-alveolar RMS. PROCEDURE: We analyzed data from 39 patients (age: 0.5-194 months, median 52) who were enrolled between 1988 and 2005 in 2 consecutive Italian Studies, RMS 88 and RMS 96. All achieved a complete resection of the residual tumor after neoadjuvant chemotherapy; 27 did not receive any other local treatment: pelvic 8, extremities 6, head-neck-non-parameningeal 5, orbit 1, genito-urinary-bladder-prostate 3, trunk 2, abdomen 1, vagina 1; 12 were given RT (32-45 Gy), 5 before and 7 after the operation: genito-urinary-bladder-prostate 3, pelvic 3, abdominal 1, extremities 1, head-neck-parameningeal 1, head-neck-non-parameningeal 1, vagina 1, orbit 1. All received postoperative chemotherapy. RESULTS: Median follow-up was 81 months (range 17-219 months). With RT: 10/12 patients are in first complete remission; 2/12 had a metastatic relapse (1 also local relapse), and both of them died of disease. Without RT: 16/27 maintained the first complete remission, however 1/16 died due to a second tumor; 8 suffered from local relapse (4 pelvic, 1 orbit, 1 vagina, 1 head-neck-non-parameningeal, 1 abdomen) and 3 of them died, 3 showed a metastatic recurrence (2 extremities, 1 pelvic) and 1 died. CONCLUSIONS: Local relapses were more frequent for patients without RT, especially in pelvic sites. The two relapses after RT occurred in huge bladder-prostate RMS. Although the limited number of patients does not allow statistically significant conclusions, our experience suggests that RT may have a positive influence on local control for completely resected non-alveolar RMS. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: To evaluate the effect of radiotherapy (RT) in association with complete second look operation, histologically confirmed, on outcome of patients with IRS Gr.III non-alveolar RMS. PROCEDURE: We analyzed data from 39 patients (age: 0.5-194 months, median 52) who were enrolled between 1988 and 2005 in 2 consecutive Italian Studies, RMS 88 and RMS 96. All achieved a complete resection of the residual tumor after neoadjuvant chemotherapy; 27 did not receive any other local treatment: pelvic 8, extremities 6, head-neck-non-parameningeal 5, orbit 1, genito-urinary-bladder-prostate 3, trunk 2, abdomen 1, vagina 1; 12 were given RT (32-45 Gy), 5 before and 7 after the operation: genito-urinary-bladder-prostate 3, pelvic 3, abdominal 1, extremities 1, head-neck-parameningeal 1, head-neck-non-parameningeal 1, vagina 1, orbit 1. All received postoperative chemotherapy. RESULTS: Median follow-up was 81 months (range 17-219 months). With RT: 10/12 patients are in first complete remission; 2/12 had a metastatic relapse (1 also local relapse), and both of them died of disease. Without RT: 16/27 maintained the first complete remission, however 1/16 died due to a second tumor; 8 suffered from local relapse (4 pelvic, 1 orbit, 1 vagina, 1 head-neck-non-parameningeal, 1 abdomen) and 3 of them died, 3 showed a metastatic recurrence (2 extremities, 1 pelvic) and 1 died. CONCLUSIONS: Local relapses were more frequent for patients without RT, especially in pelvic sites. The two relapses after RT occurred in huge bladder-prostate RMS. Although the limited number of patients does not allow statistically significant conclusions, our experience suggests that RT may have a positive influence on local control for completely resected non-alveolar RMS. (c) 2008 Wiley-Liss, Inc.
Authors: Beverly Raney; Julie Stoner; James Anderson; Richard Andrassy; Carola Arndt; Ken Brown; William Crist; Harold Maurer; Stephen Qualman; Moody Wharam; Eugene Wiener; William Meyer; Andrea Hayes-Jordan Journal: J Pediatr Surg Date: 2010-11 Impact factor: 2.545
Authors: Julie A Bradley; Mark L Kayton; Yueh-Yun Chi; Douglas S Hawkins; Jing Tian; John Breneman; Suzanne L Wolden; David Walterhouse; David A Rodeberg; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-20 Impact factor: 7.038
Authors: John Breneman; Jane Meza; Sarah S Donaldson; R Beverly Raney; Suzanne Wolden; Jeff Michalski; Fran Laurie; David A Rodeberg; William Meyer; David Walterhouse; Douglas S Hawkins Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038
Authors: David A Rodeberg; Moody D Wharam; Elizabeth R Lyden; Julie A Stoner; Kenneth Brown; Suzanne L Wolden; Charles N Paidas; Sarah S Donaldson; Douglas S Hawkins; Sheri L Spunt; Carola A Arndt Journal: Int J Cancer Date: 2014-12-10 Impact factor: 7.396
Authors: Timothy B Lautz; Yueh-Yun Chi; Minjie Li; Suzanne L Wolden; Dana L Casey; Jonathan C Routh; Candace F Granberg; Odion Binite; Erin R Rudzinski; Douglas S Hawkins; Rajkumar Venkatramani; David A Rodeberg Journal: Cancer Date: 2020-10-20 Impact factor: 6.921